Allarity Therapeutics (ALLR)
Develops stenoparib with DRP®-guided patient selection for advanced recurrent ovarian cancer.
Something off on this page? Send us feedback.
Develops investigational stenoparib for advanced recurrent ovarian cancer with a DRP® companion diagnostic. The clinical-stage company concentrates development on this program and does not have an approved oncology product portfolio.
Develops stenoparib, an investigational PARP/tankyrase inhibitor for advanced recurrent ovarian cancer, alongside its drug-specific DRP® companion diagnostic. The clinical-stage model uses DRP® to identify patients expected to derive benefit, pairing treatment development with patient selection instead of a marketed oncology product portfolio.
Listed in the United States, this Danish-origin company maintains a Florida executive office and a Danish research operation while concentrating development on stenoparib. FDA Fast Track designation applies to the program but does not constitute marketing approval.
Progress depends on clinical development, FDA regulatory review, DRP®-based patient selection, and continued access to external financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.0M · Total debt $22.3M · Total assets $32.1M · Shareholders' equity $3.5M
- Revenue
- $0
- Operating income
- −$2.7M
- Net income
- −$3.4M
No dividends on record.
| Insiders6 holders · as of May 14, 2026 | 8.22% | 1.31M shares | |
| Otherremainder | 91.78% | 14.60M shares |
15.91M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Thomas JensenInsiderofficer: CEO | 3.75% | 596,734 | Form 4filed May 14, 2026 ↗ |
Jeremy R. GraffInsiderofficer: See Remarks | 2.40% | 381,644 | Form 4filed Apr 30, 2026 ↗ |
Jeffrey S. ErvinInsiderofficer: CFO | 0.94% | 150,000 | Form 4filed Apr 30, 2026 ↗ |
Alexander EpshinskyInsiderofficer: CFO | 0.53% | 85,051 | Form 4filed Jan 24, 2025 ↗ |
Gerald W. McLaughlinInsiderdirector | 0.44% | 70,000 | Form 4filed May 7, 2026 ↗ |
| See all 15 → | |||
Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- AstraZeneca (ADR)
Lynparza is a PARP inhibitor with U.S. ovarian-cancer maintenance uses
- GSK (ADR)
Zejula is a PARP inhibitor for HRD-positive ovarian maintenance
- Zentalis Pharmaceuticals
Biomarker-selected candidate for platinum-resistant ovarian cancer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Allarity Therapeutics | $1.40 | −1.41% | $22.4M | — | — | 65.0 | +5,233.3% |
| AstraZeneca (ADR) | $163.77 | +1.31% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| GSK (ADR) | $50.65 | +0.45% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Zentalis Pharmaceuticals | $3.79 | +0.26% | $268.4M | — | — | — | — |
| Median | 20.0 | 12.2 | 3.2 | +4.6% |